Applications of Cytidine-5'-Triphosphoric Acid Disodium Salt in Industrial Manufacturing

Cytidine-5'-Triphosphoric Acid Disodium Salt (CTP-Na2) serves specialized roles in multiple industrial processes, particularly where high-purity nucleotide derivatives are critical for chemical synthesis, biotechnology, and diagnostics manufacturing. Below, we detail its established downstream applications, each with industry-specific compliance guidance, compounding ratios, integration stages, and common final product types.

1. Oligonucleotide Synthesis for Diagnostic Kits

Downstream producers use this compound as a nucleotide substrate during automated oligonucleotide assembly for in vitro diagnostic (IVD) probes, primers, and molecular beacon production. CTP-Na2 is inserted for direct chain elongation where cytidine residues are required, ensuring sequence fidelity and efficient phosphoramidite cycle runs under regulated, controlled conditions across IVD manufacturing facilities worldwide.

Industry compliance standards

• ISO 13485:2016 for diagnostic medical device manufacturing
• USP General Chapter <1047> Biological Assay Validation
• 21 CFR Part 820 Quality System Regulation (QSR) for IVDs
• CE-IVD and EU IVDR for distribution in Europe

Typical usage ratio

• 0.25–1.5 μmol per nucleotide incorporation step, typically adjusted to sequence complexity and final probe concentration

Downstream process integration

• Enters solid-phase or solution-based oligonucleotide synthesis workstation following phosphoramidite coupling steps and CTP-specific chain extension protocols

Final product types

• Real-time PCR diagnostic kits
• Fluorescent-labeled DNA probes
• Genetic sequencing library kits
• Custom research-use oligonucleotides

2. Enzymatic Synthesis of Nucleic Acid Therapeutics

Specialty pharma manufacturers utilize this compound in the enzymatic assembly of antisense oligonucleotides, siRNA, and mRNA intermediates. CTP-Na2 serves as a critical nucleotide donor during template-dependent or template-independent polymerase reactions, ensuring batch-to-batch consistency and compliance with high-purity nucleic acid API requirements under GMP environments.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• USP/NF Monograph for Therapeutic Oligonucleotides
• Ph. Eur. General Text 5.23 for nucleic acid APIs
• FDA DMF filing for nucleotide raw materials

Typical usage ratio

• 1–15 mM in reaction buffer, adjusted based on enzyme system and required yield of final nucleic acid strand

Downstream process integration

• Added after template and primer loading, before initiation of in vitro transcription or polymerase extension processes in single-use reactors or bioprocessors

Final product types

• Antisense oligonucleotide drugs
• siRNA duplexes for gene silencing
• mRNA vaccine intermediates
• Custom synthesized nucleic acid APIs

3. Industrial-Scale Production of Nucleotide Sugars

Companies in the fine chemicals sector depend on this input for the biocatalytic production of cytidine diphosphate (CDP)-sugars and uridine/cytidine hybrid sugar nucleotides. The compound acts as a cytidine phosphate donor in enzyme-catalyzed conversion reactions for manufacturing pharmaceutical-grade nucleotide sugars essential for glycosylation control in biological recombinant protein production and rare carbohydrate synthesis.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• REACH Annex IV/V substance register (EU)
• USP/NF for excipient-grade nucleotide sugars
• GMP guidelines for raw material traceability

Typical usage ratio

• 0.1–1.2 molar equivalents relative to sugar phosphate substrate, refined per process optimization and intended glycosylation specificity

Downstream process integration

• Charged to fed-batch or continuous flow bioreactors with recombinant transferase enzymes, prior to downstream purification and crystallization modules

Final product types

• CDP-choline for pharmaceutical use
• CDP-glycerol for vaccine polysaccharide synthesis
• Cytidine-labeled rare sugars for diagnostics
• Nucleotide sugar intermediates for API manufacturing

4. Cell-Free Protein Synthesis (CFPS) Reagent Manufacturing

Producers of cell-free transcription/translation reagent kits rely on this material to maintain sufficient nucleotide triphosphates in cell-free lysate formulations. CTP-Na2 supports efficient mRNA transcription and correct codon incorporation during in vitro coupled transcription-translation reactions, critical for rapid prototyping in protein engineering and synthetic biology contract manufacturing organizations.

Industry compliance standards

• cGMP for reagent-grade chemical manufacturing
• ISO 9001:2015 for laboratory product production
• USP <1047> for biologics research use reagents
• OECD GLP (Good Laboratory Practice) for kit components

Typical usage ratio

• 1–5 mM in reaction solution, optimized according to protein template requirements and system throughput volume

Downstream process integration

• Incorporated into lyophilized or liquid CFPS kits during final formulation blending and post-sterilization fill/finish processes

Final product types

• Ready-to-use cell-free protein synthesis kits
• Custom translation transcription kits for biotech R&D
• High-throughput protein screening platforms
• Academia and biopharma research reagents

5. Substrate in Nucleoside-Analog API Synthesis

Advanced pharmaceutical synthesis routes utilize this salt as a critical intermediate for nucleoside-analog APIs. During semi-synthetic or total synthesis of anti-viral or anti-tumor nucleoside analogs, the compound forms part of phosphorylation, protection, and coupling steps where highly specific cytidine-derived triphosphates are required for downstream transformation into diverse, commercial, or clinical active substances.

Industry compliance standards

• ICH Q11 for API manufacturing process development
• USP Monograph for relevant nucleoside analog APIs
• FDA 21 CFR Part 211 for finished pharmaceutical products
• Ph. Eur. individual monographs for cytidine derivatives

Typical usage ratio

• 0.5–2.0 equivalents, calculated in relation to nucleoside core input and desired conversion efficiency

Downstream process integration

• Fed to reactor post-protection group introduction, before downstream deprotection and API isolation steps

Final product types

• Cytarabine and related anti-cancer drugs
• Customized nucleoside analog active ingredients
• Therapeutic nucleotide prodrugs
• Pharmaceutical research intermediates